Market Overview

UPDATE: Brinson Patrick Initiates Coverage on MannKind Corporation with Market Outperform Rating, $6 PT

Share:
Related MNKD
Analyst Sees 'No Reason' To Own MannKind
Vetr Top Raters Upgrade MannKind To 5-Star Stock

In a report published Monday, Brinson Patrick initiated coverage on MannKind Corporation (NASDAQ: MNKD) with a Market Outperform rating and $6.00 price target.

Brinson Patrick noted, “MannKind Corporation's rapid-acting insulin, Afrezza, is currently in two Phase 3 pivotal trials with their handheld drug delivery device called Dreamboat. We believe the two Complete Response letters they received with their previous device has created a buying opportunity for investors today. Following a completion of a financing that carries them through 2013, we recommend investors begin accumulating MNKD shares.”

MannKind Corporation closed on Friday at $2.13.

Latest Ratings for MNKD

DateFirmActionFromTo
Nov 2015Griffin SecuritiesDowngradesBuyNeutral
Nov 2015RBC CapitalDowngradesOutperformUnderperform
Sep 2015Piper JaffrayDowngradesNeutralUnderweight

View More Analyst Ratings for MNKD
View the Latest Analyst Ratings

Posted-In: Brinson PatrickAnalyst Color Initiation Analyst Ratings

 

Related Articles (MNKD)

View Comments and Join the Discussion!

Get Benzinga's Newsletters